Form 4: Biogen Executive Robin Kramer Reports Stock Transactions
SEC Form 4 Filing
Chief Accounting Officer Robin Kramer reported the acquisition and disposal of Biogen Inc. stock and restricted stock units on February 7, 2025.
Summary
- Robin Kramer, Chief Accounting Officer of Biogen Inc., filed a Form 4 detailing changes in beneficial ownership.
- On February 7, 2025, Kramer acquired 788 shares of common stock through the vesting of restricted stock units and disposed of 232 shares to cover tax obligations at a price of $141.35 per share, resulting in a net holding of 7,195.7483 shares.
- Additionally, Kramer acquired 703 shares of common stock through the vesting of restricted stock units and disposed of 244 shares to cover tax obligations at a price of $141.35 per share, resulting in a net holding of 7,422.7483 shares.
- Kramer also reported holding 10,535 restricted stock units, which vest in three equal yearly installments beginning on February 6, 2025.
- The reported transactions were signed by Samuel Ntonme, attorney-in-fact for Robin Kramer, on February 10, 2025.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with no inherent positive or negative sentiment. It reflects standard executive compensation practices.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's performance and future prospects. Form 4 filings are a standard part of regulatory compliance.
Comparison to Industry Standards
- Executive compensation packages, including restricted stock units, are a standard practice among publicly traded biotechnology companies like Biogen.
- The vesting schedules and terms of these units are generally comparable to those offered by peer companies such as Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX).
- These companies use equity-based compensation to align executive interests with shareholder value and incentivize long-term performance.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.
- Employees may be indirectly affected by the perceived alignment of executive interests with company performance.
Key Dates
| Date | Description |
|---|---|
| 02/08/2023 | Grant date for restricted stock units vesting in three equal annual installments commencing one year after this date. |
| 02/07/2024 | Grant date for restricted stock units vesting in three equal annual installments commencing one year after this date. |
| 02/06/2025 | Date of earliest transaction and first vesting date for 10,535 restricted stock units. |
| 02/07/2025 | Transaction date for stock acquisitions and disposals. |
| 02/08/2026 | Expiration date for some restricted stock units. |
| 02/07/2027 | Expiration date for some restricted stock units. |
| 02/10/2025 | Date of signature by attorney-in-fact. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Biogen, BIIB, Kramer, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.